Individualized therapy in non-small-cell lung cancer: Future versus current clinical practice

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Despite advances in the management of non-small-cell lung cancer (NSCLC), including the introduction of targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors, improvements in survival are marginal and the overall prognosis for patients remains poor. Tailoring therapy to the individual patient is a promising approach for selecting the most appropriate therapeutic regimens to maximize efficacy and minimize toxicity. The identification of predictive biomarkers that can guide treatment decisions is an important step for individualized therapy and in ultimately improving patient outcomes. Genomic and proteomic studies provide a means for the molecular profiling of tumor tissue from patients with NSCLC, and allow tailoring of therapy whereby the most appropriate treatment is administered to each individual patient. Although there are still significant challenges to implementing genomic and proteomic testing in clinical practice, the rapid development of newer technologies provides hope for overcoming these barriers.

Original languageEnglish (US)
JournalOncogene
Volume28
Issue numberSUPPL. 1
DOIs
StatePublished - Aug 2009

Fingerprint

Non-Small Cell Lung Carcinoma
Proteomics
Therapeutics
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Biomarkers
Technology
Survival
Neoplasms

Keywords

  • Biomarker
  • EGFR
  • Genomics
  • Proteomics

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Individualized therapy in non-small-cell lung cancer : Future versus current clinical practice. / Perez-Soler, Roman.

In: Oncogene, Vol. 28, No. SUPPL. 1, 08.2009.

Research output: Contribution to journalArticle

@article{fdc1a69042c749e38f2af1f0b042c034,
title = "Individualized therapy in non-small-cell lung cancer: Future versus current clinical practice",
abstract = "Despite advances in the management of non-small-cell lung cancer (NSCLC), including the introduction of targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors, improvements in survival are marginal and the overall prognosis for patients remains poor. Tailoring therapy to the individual patient is a promising approach for selecting the most appropriate therapeutic regimens to maximize efficacy and minimize toxicity. The identification of predictive biomarkers that can guide treatment decisions is an important step for individualized therapy and in ultimately improving patient outcomes. Genomic and proteomic studies provide a means for the molecular profiling of tumor tissue from patients with NSCLC, and allow tailoring of therapy whereby the most appropriate treatment is administered to each individual patient. Although there are still significant challenges to implementing genomic and proteomic testing in clinical practice, the rapid development of newer technologies provides hope for overcoming these barriers.",
keywords = "Biomarker, EGFR, Genomics, Proteomics",
author = "Roman Perez-Soler",
year = "2009",
month = "8",
doi = "10.1038/onc.2009.200",
language = "English (US)",
volume = "28",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Individualized therapy in non-small-cell lung cancer

T2 - Future versus current clinical practice

AU - Perez-Soler, Roman

PY - 2009/8

Y1 - 2009/8

N2 - Despite advances in the management of non-small-cell lung cancer (NSCLC), including the introduction of targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors, improvements in survival are marginal and the overall prognosis for patients remains poor. Tailoring therapy to the individual patient is a promising approach for selecting the most appropriate therapeutic regimens to maximize efficacy and minimize toxicity. The identification of predictive biomarkers that can guide treatment decisions is an important step for individualized therapy and in ultimately improving patient outcomes. Genomic and proteomic studies provide a means for the molecular profiling of tumor tissue from patients with NSCLC, and allow tailoring of therapy whereby the most appropriate treatment is administered to each individual patient. Although there are still significant challenges to implementing genomic and proteomic testing in clinical practice, the rapid development of newer technologies provides hope for overcoming these barriers.

AB - Despite advances in the management of non-small-cell lung cancer (NSCLC), including the introduction of targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors, improvements in survival are marginal and the overall prognosis for patients remains poor. Tailoring therapy to the individual patient is a promising approach for selecting the most appropriate therapeutic regimens to maximize efficacy and minimize toxicity. The identification of predictive biomarkers that can guide treatment decisions is an important step for individualized therapy and in ultimately improving patient outcomes. Genomic and proteomic studies provide a means for the molecular profiling of tumor tissue from patients with NSCLC, and allow tailoring of therapy whereby the most appropriate treatment is administered to each individual patient. Although there are still significant challenges to implementing genomic and proteomic testing in clinical practice, the rapid development of newer technologies provides hope for overcoming these barriers.

KW - Biomarker

KW - EGFR

KW - Genomics

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=68949215137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949215137&partnerID=8YFLogxK

U2 - 10.1038/onc.2009.200

DO - 10.1038/onc.2009.200

M3 - Article

C2 - 19680295

AN - SCOPUS:68949215137

VL - 28

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - SUPPL. 1

ER -